Editas Medicine Inc. (EDIT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 56% of 52W Range • RSI-14 at 50.8 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While EDIT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.76) and Max Pain ($3.08) forces dealer call-delta covering toward $4.14.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Editas Medicine Inc. (EDIT) slipped -0.68% to $2.93, trading at 56% of its 52-week range ($1.66 – $3.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Key players include Beam Therapeutics, Twist Bioscience, Sangamo, Editas Medicine and Tessera Therapeutics. Profiles cover gene-writing technologies, products, applications, trends and competition.Dublin, Oct. 29, 2026 (
For questions about this article or underlying research, email help@trefis.com.
For questions about this article or underlying research, email help@trefis.com.
Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EDIT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EDIT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Editas Medicine Inc. (EDIT) ranks #747 by composite RQD confidence (37/100, grade D-) and #466 by equity capitalization ($450.0M). Within this direct 5-issuer industry benchmark cohort, EDIT leads on earnings valuation at N/A trailing P/E, while EDIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with EDIT at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EDIT
ACTIVE
Editas Medicine Inc. | D- | 37/100 | — | — | -35.0% | -0.68% | $450.0M | Benchmark Subject |
| PROK ProKidney Corp. (Class A) | D | 44/100 | — | — | -35.0% | -3.29% | $444.4M | /prok-vs-edit → |
| ALLO Allogene Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -3.85% | $431.9M | /allo-vs-edit → |
| AUTL Autolus Therapeutics plc | E | 25/100 | — | -27.8% | -35.0% | -3.07% | $420.5M | /autl-vs-edit → |
| RGNX REGENXBIO Inc. | D- | 39/100 | — | — | -35.0% | +2.35% | $489.2M | /rgnx-vs-edit → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Editas Medicine Inc. (EDIT) reported GAAP revenue of $40.5M (+25.4% vs. FY2024 revenue of $32.3M , and -48.1% cumulative change since FY2023) , GAAP net income of -$160.1M, operating cash flow of -$165.2M, and free cash flow of -$165.8M (+24.3% YoY). On the balance sheet, EDIT closed FY2025 with $186.5M in total assets against $53.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.5M | -$160.1M | -$165.2M | -$165.8M | $186.5M | $53.6M |
| FY2024 (FY) | 2024-12-31 | $32.3M | -$237.1M | -$210.3M | -$219.1M | $341.6M | $52.4M |
| FY2023 (FY) | 2023-12-31 | $78.1M | -$153.2M | -$132.2M | -$132.2M | — | — |
As of 2026-11-01, Editas Medicine Inc. (NASDAQ: EDIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.93 (-0.68% 1D, market cap $450.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EDIT ranks #747 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M) and ALLO (Allogene Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).
Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
EDIT last traded at $2.93 (-0.68% on volume of 3,226,724 shares), positioning the stock +6.16% above its 50-day simple moving average ($2.76) and +9.33% above its 200-day simple moving average ($2.68). Across its 52-week range of $1.66 to $3.94, EDIT sits at the 55.7% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.56 to $3.30).
Why EDIT Stock slipped -0.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.